Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Recruiting 4Not yet recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5Observational 3

Sponsor

Cancer Type

Breast 25Gastrointestinal 14Other hematologic neoplasm 13Head & Neck 5Thoracic 4Lymphoid 4Sarcoma 3Plasma cell 3Gynecologic 3Classical hematology 3Myeloid 2Other neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Head and Neck Neoplasms 2095Squamous Cell Carcinoma of Head and Neck 1649Nasopharyngeal Carcinoma 517Thyroid Neoplasms 477Carcinoma, Non-Small-Cell Lung 435Breast Neoplasms 314Mouth Neoplasms 312Neoplasms 309Melanoma 299Oropharyngeal Neoplasms 285Colorectal Neoplasms 272Lung Neoplasms 246Carcinoma, Squamous Cell 239Neoplasm Metastasis 235Ovarian Neoplasms 226Uterine Cervical Neoplasms 202Stomach Neoplasms 195Salivary Gland Neoplasms 192Laryngeal Neoplasms 192Nasopharyngeal Neoplasms 188Carcinoma, Renal Cell 182Esophageal Neoplasms 179Pancreatic Neoplasms 176Prostatic Neoplasms 157Sarcoma 142Urinary Bladder Neoplasms 135Triple Negative Breast Neoplasms 134Recurrence 127Endometrial Neoplasms 123Hypopharyngeal Neoplasms 121

Interventions

toripalimab 1nimotuzumab 1Radiotherapy 1Neoadjuvant Therapy 1Immunotherapy 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Pathologic Complete Response × Head & Neck × Clear all
NCT07538206 2026-04-20

Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma

Tang-Du Hospital

Phase 1/2 Not yet recruiting
10 enrolled
Head & Neck

Pathologic Complete Response, Head and Neck Neoplasms

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Tang-Du Hospital

Phase 2 Recruiting
10 enrolled
Head & Neck

Pathologic Complete Response, Head and Neck Neoplasms

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Sun Yat-sen University

Phase 3 Recruiting
456 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Recruiting
346 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting
208 enrolled
Head & Neck

Pathologic Complete Response, Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡